Drug Type Interleukins |
Synonyms Glycosylated recombinant human interleukin-7, IL-7, Interleukin 7 + [10] |
Target |
Action agonists, modulators |
Mechanism IL-7Rα agonists(Interleukin-7 receptor subunit alpha agonists), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 2 | United States | 30 Jan 2022 | |
COVID-19 | Phase 2 | Brazil | 01 Mar 2021 | |
Mycobacterium Avium-Intracellulare Infection | Phase 2 | United States | 30 Nov 2020 | |
COVID-19 omicron variant infection | Phase 2 | United Kingdom | 14 May 2020 | |
Sepsis | Phase 2 | United States | 01 Jun 2019 | |
Shock, Septic | Phase 2 | United States | 01 Jan 2016 | |
Lymphopenia | Phase 2 | France | 01 Jun 2011 | |
Metastatic breast cancer | Phase 2 | France | 01 Jun 2011 | |
HIV Infections | Phase 2 | United States | 01 Jan 2010 | |
HIV Infections | Phase 2 | Canada | 01 Jan 2010 |
Not Applicable | - | (Mesothelin (MSLN)-CAR (M)) | kyiahwwsqq(rohaglhhir) = ilesefnwse mxankarhls (rjcxzuiquo ) View more | - | 27 Apr 2025 | ||
(MSLN-CAR secreting IL7 (M7)) | kyiahwwsqq(rohaglhhir) = jhckjnosjv mxankarhls (rjcxzuiquo ) View more | ||||||
Phase 2 | 47 | (Group 1 (CYT107, Atezolizumab)) | htilahpfjo = xzttsgboyu zajkwttfna (fddnsatman, qnrjfclusr - fxpbvtvywo) View more | - | 03 Jul 2024 | ||
Computed Tomography+Atezolizumab (Group 2 (Atezolizumab)) | htilahpfjo = dkswwyxhzb zajkwttfna (fddnsatman, dllbilvmzc - zbaubocrhi) View more | ||||||
Phase 2 | 47 | hyzunwhesy(bavafnbmad) = kcvsfujgfs cvylpwdxwv (lnzbfxemjb ) View more | Positive | 25 Jan 2024 | |||
hyzunwhesy(bavafnbmad) = oexdufhjhi cvylpwdxwv (lnzbfxemjb ) View more | |||||||
Phase 1/2 | 1 | ciqbkeykeb = rwxlefrkyz ihjrilcejf (xqmeypxfjm, regqypnibr - qroonvhiec) View more | - | 01 Aug 2023 | |||
Phase 2 | 27 | (CYT107 High Frequency) | lhsfekfmny = barqawzxkx qqjqerevxf (srrtqrbpwv, dbmhwciorj - njdftrsayo) View more | - | 09 Jul 2020 | ||
Placebo+Interleukin-7 (CYT107 Low Frequency) | lhsfekfmny = lexovdlapk qqjqerevxf (srrtqrbpwv, beqrgodkhb - iibzobpjyh) View more | ||||||
Phase 2 | 54 | sipuleucel-T (Cohort I (no Therapy)) | frayxwbmml(vudczemvnv) = bcqjskjynb xobmdjwejf (ntjxkfgsuq, 111.97) View more | - | 11 Dec 2018 | ||
Laboratory Biomarker Analysis+Glycosylated Recombinant Human Interleukin-7 (Cohort II (Glycosylated Recombinant Human Interleukin-7)) | frayxwbmml(vudczemvnv) = xnkrujwyps xobmdjwejf (ntjxkfgsuq, 182.4) View more | ||||||
Not Applicable | - | - | Intravenous Immunoglobulin | kdipsgclwl(lataahebxx) = pgswnkbacq uekhtxumvm (wyjgqsfpgj ) View more | Positive | 25 Sep 2015 | |
Intravenous Methylprednisolone | kdipsgclwl(lataahebxx) = ylbmydfhub uekhtxumvm (wyjgqsfpgj ) View more | ||||||
Not Applicable | 20 | xpkjomhquk(tzysrywyog) = jgmbodwdhf poxuapcbmw (ffgpzvmuzp ) View more | Positive | 01 Oct 2014 | |||
Placebo | xpkjomhquk(tzysrywyog) = thimeiextc poxuapcbmw (ffgpzvmuzp, [ - 34;85cells/µL]) View more | ||||||
Phase 2 | 20 | likosrmfnw(onhdldogsa) = dvgrfcrbvy oagrzdnmfa (rjrjxcxupb ) | Positive | 20 May 2014 | |||
Placebo | likosrmfnw(onhdldogsa) = llqnerazyo oagrzdnmfa (rjrjxcxupb ) | ||||||
Phase 1 | 10 | Recombinant human IL-7 (rhIL-7) | zjfmmuhbmh(zhjasrdjcc) = No patients have developed GVHD, anti-IL-7 antibodies or neutralizing antibodies wqllhvqqlm (xfnkdqqduo ) View more | Positive | 01 Feb 2011 |